Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor Demirci et al1 reported the successful treatment of a primary B-cell mucosa-associated lymphoid tissue (MALT) lymphoma of the iris with rituximab. The diagnosis was based on fine-needle aspiration (FNA) cytology findings described as “a monomorphic population of small to medium-sized hyperchromatic, CD20+ lymphocytes.”1 A few reactive CD3+ reactive lymphocytes were also observed. The results of other immunohistochemical stains were not reported, nor were any adjunct studies such as flow cytometric immunophenotyping or polymerase chain reaction for IgH gene rearrangement obtained.
Margo CE. Contemplating the Diagnostic Certainty of Primary Iris Mucosa-Associated Lymphoid Tissue Lymphoma. JAMA Ophthalmol. 2015;133(8):969–970. doi:10.1001/jamaophthalmol.2015.1153
Customize your JAMA Network experience by selecting one or more topics from the list below.